利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

64 条记录 (耗时 0.021 秒)

    PRODUCTION OF PLURIPOTENT GRANULOCYTE COLONY-STIMULATING FACTOR
    4.
    发明授权
    PRODUCTION OF PLURIPOTENT GRANULOCYTE COLONY-STIMULATING FACTOR 失效
    多功能颗粒细胞集落刺激因子的生产

    公开(公告)号：EP0237545B2

    公开(公告)日：1999-08-25

    申请号：EP86905530.1

    申请日：1986-08-22

    申请人： Kirin-Amgen, Inc.

    发明人： SOUZA, Lawrence, M.

    IPC分类号： C12N15/27 ,  C12P19/34 ,  C12P21/02 ,  C07K14/535 ,  A61K38/17

    CPC分类号： C07K16/243 ,  A61K38/00 ,  C07K14/535

    摘要： Novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor (''hpG-CSF'') which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.

    摘要翻译： 具有部分或全部主要结构构象和哺乳动物（例如人）多能粒细胞集落刺激因子（“hpG-CSF”）的一种或多种生物学特性的新多肽， 原核或真核宿主表达外源DNA序列的产物。 编码hpG-CSF的氨基酸残基序列的部分或全部或其类似物的序列可以整合到自主复制的质粒或病毒载体中，用于将合适的原核真核宿主细胞例如细菌，酵母或脊椎动物细胞转化或转染入 文化。 表达DNA序列的产物表现出例如源自天然来源的hpG-CSF分离物的物理和免疫学性质以及体外生物学活性。 还公开了共享hpG-CSF的生物化学和免疫学性质的化学合成的多肽。

    Oral dosage form of biologically active proteins
    6.
    发明公开
    Oral dosage form of biologically active proteins 失效
    埃里维斯托夫。

    公开(公告)号：EP0459795A1

    公开(公告)日：1991-12-04

    申请号：EP91304885.6

    申请日：1991-05-30

    申请人： Kirin-Amgen, Inc.

    发明人： Nomura, Hideaki ,  Maruyama, Kazutoshi

    IPC分类号： A61K37/02 ,  A61K9/48

    CPC分类号： A61K9/5042 ,  A61K9/1617 ,  A61K9/2013 ,  A61K9/2866 ,  A61K9/4858 ,  A61K9/4891 ,  A61K38/1816 ,  A61K38/193

    摘要： An oral dosage form comprising

    (a) granulocyte colony-stimulating factor or erythropoietin,
    (b) surfactant(s),
    (c) fatty acid(s), and
    (d) enteric material.

    With the oral drug preparations provided by the present invention, therefore, inactivation of the principal ingredient during the process of pharmaceutical manufacturing has been shown to be avoided along with proven effects such as enhanced absorption of the principal ingredient from the intestinal tract particularly as a result of the addition of fatty acid to the drug composition.
    These may be said not only to lead to a dosage reduction but also to facilitate accurate dose control and increase the practical usefulness of the bioactive proteins in the form of oral preparations.

    摘要翻译： 包含（a）粒细胞集落刺激因子或促红细胞生成素，（b）表面活性剂，（c）脂肪酸和（d）肠溶性物质）的口服剂型。 因此，在本发明提供的口服药物制剂中，已证明可以避免药物制造过程中主要成分的失活，同时还证明了其主要成分从肠道吸收增强，尤其是其结果 向药物组合物中加入脂肪酸。 这些可以说不仅导致剂量减少，而且还可以促进准确的剂量控制并增加口服制剂形式的生物活性蛋白质的实用性。

    CHEMICALLY MODIFIED GRANULOCYTE COLONY STIMULATING FACTOR
    8.
    发明公开
    CHEMICALLY MODIFIED GRANULOCYTE COLONY STIMULATING FACTOR 失效
    化学改性剂GRANULOCYTENKOLONIE ERREGENDER FAKTOR。

    公开(公告)号：EP0401384A1

    公开(公告)日：1990-12-12

    申请号：EP90900360.0

    申请日：1989-12-22

    申请人： Kirin-Amgen, Inc.

    发明人： ISHIKAWA, Rika ,  OKADA, Yuji ,  KAKITANI, Makoto

    IPC分类号： C07K14/00 ,  C07K1/00 ,  A61K38/00

    CPC分类号： C07K17/08 ,  A61K38/00 ,  A61K47/60 ,  C07K14/535 ,  Y10S930/145

    摘要： This invention provides a chemically modified protein prepared by combining polyethylene glycol with a polypeptide having substantially the following amino acid sequence and comprising the product of manifestation by a host cell of a foreign DNA sequence (1), wherein n is 0 or 1. This protein has a more lasting action of increasing neutrophils than that of the human granulocyte colony stimulating factor (G-CSF) known heretofore.

    摘要翻译： 一种新的化学修饰的蛋白质由人类粒细胞集落刺激因子（G-CSF）（在专利中给出的174个单元（或具有N-末端甲硫氨酸的175个氨基酸序列））（由来自外来DNA序列的宿主细胞表达） 通过氨基gps的聚乙二醇。 的氨基酸残基或通过羧基gps。

    Method for treating iron overload
    10.
    发明公开
    Method for treating iron overload 失效
    Methode zur Behandlung derEisenübersättigung。

    公开(公告)号：EP0269394A2

    公开(公告)日：1988-06-01

    申请号：EP87310300.6

    申请日：1987-11-20

    申请人： Kirin-Amgen, Inc.

    发明人： Adamson, John William ,  Downing, Michael Richard ,  Eschbach, Joseph Wetherill ,  Egrie, Joan Christine

    IPC分类号： A61K37/24

    CPC分类号： A61K38/1816

    摘要： A method for reducing stored iron and serum iron in mammals is disclosed. In particular, a mammal having an iron overload disorder is administered a therapeutically effective amount of erythropoietin to increase red blood cell production and the mammal is subsequently phlebotomized to remove the excess red blood cells produced.

    摘要翻译： 公开了一种用于减少哺乳动物中储存的铁和血清铁的方法。 特别地，给予具有铁超负荷病症的哺乳动物治疗有效量的促红细胞生成素以增加红细胞生成，随后静脉切开哺乳动物以除去产生的多余红细胞。